Can you share some?Just search some of the reviews in this forum. Many are not very positive about this stuff
Do the search yourself.Can you share some?
I think DHT is a scam.Do the search yourself.
The numbers show statistically significant and clinically meaningful hair growth outcomes, while demonstrating excellent safety. A total of 666 patients were treated for 24 weeks.The effect is very limited.
The half-life is approximately 6–8 hours.Someone know prylitamide half life?
The efficacy of 826 is inferior to that of ru, so why not choose ru? Besides, both 826 and ru have drug resistance.The numbers show statistically significant and clinically meaningful hair growth outcomes, while demonstrating excellent safety. A total of 666 patients were treated for 24 weeks.
Both the 1.0% BID (i.e. twice a day) group and 0.5% BID group demonstrated statistically significant therapeutic efficacy and clinical significance relative to the placebo group. The target area non-vellus hair counts (“TAHC”) of the 1.0% BID group showed an increase of 15.33 hairs/cm2 from baseline. The TAHC of the 0.5% BID group showed an increase of 14.46 hairs/cm2 from baseline. The TAHC of the placebo group showed an increase of 4.68 hairs/cm2 from baseline.
The efficacy of 826 is inferior to that of ru, so why not choose ru? Besides, both 826 and ru have drug resistance.Tell us more.
Do you have expireirnce with this product?
Gemini say prylitamide is stronger that ru.The efficacy of 826 is inferior to that of ru, so why not choose ru? Besides, both 826 and ru have drug resistance.
For me, the only advantage of this medicine is that it can be more conveniently purchased from legitimate channels as genuine products.
RU58841 has no published clinical safety or efficacy data in humans.The efficacy of 826 is inferior to that of ru, so why not choose ru? Besides, both 826 and ru have drug resistance.
For me, the only advantage of this medicine is that it can be more conveniently purchased from legitimate channels as genuine products.
Yes. In preclinical binding assays, pyrilutamide demonstrates significantly higher potency than other prominent androgen receptor antagonists.Gemini say prylitamide is stronger that ru.
If I'm already using finasteride, why would I need 826?Combining pyrilutamide with a 5-alpha reductase inhibitor significantly lowers overall DHT levels in the scalp.
If the effect of 826 is really that good, the first phase III clinical trial won't fail.Gemini say prylitamide is stronger that ru.
The second phase III clinical trial was successful.If the effect of 826 is really that good, the first phase III clinical trial won't fail.
You brought up ''drug resistance'' and all I said was that in individuals who have exceptionally high systemic or localised scalp DHT levels, the available dose of pyrilutamide may simply be overwhelmed (as it physically must outcompete the DHT molecules already present in the scalp). In these cases, it appears as though the body is "resistant" to the drug, when in reality, the treatment is just being outcompeted. Combining with a 5-alpha reductase inhibitor would (significantly) lower overall DHT levels in the scalp. With fewer DHT molecules present to compete, pyrilutamide can bind to the remaining androgen receptors much more effectively. Using both together could synergise (as each has a different mechanism of action).If I'm already using finasteride, why would I need 826?
Can you share it?The second phase III clinical trial was successful.
Per Kintor, pyrilutamide has entered the new drug application stage in China. If the application is successful with Chinese regulators (similar to the US FDA and EU EMA), the company expects that it will reach commercialisation in 2027. Outside China it is sold directly to consumers as a cosmetic.
You brought up ''drug resistance'' and all I said was that in individuals who have exceptionally high systemic or localised scalp DHT levels, the available dose of pyrilutamide may simply be overwhelmed (as it physically must outcompete the DHT molecules already present in the scalp). In these cases, it appears as though the body is "resistant" to the drug, when in reality, the treatment is just being outcompeted. Combining with a 5-alpha reductase inhibitor would (significantly) lower overall DHT levels in the scalp. With fewer DHT molecules present to compete, pyrilutamide can bind to the remaining androgen receptors much more effectively. Using both together could synergise (as each has a different mechanism of action).
That said, pyrilutamide has single-agent activity, so can be used alone.
What does it mean in simple words?
